Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma for the commercial manufacture of Retavase® (reteplase), a fibrinolytic agent that has been marketed in North America since October 1996.
Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI.